Bijan Shahbazkhani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bijan Shahbazkhani has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Arash Kazemi
Department of Internal Medicine, Gut and Liver Research Center, Non-Communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication - Azarakhsh Baghdadi
Rheumatology Research Center, Tehran University of Medical Sciences, Iran
1 shared publication - Danial Masoumi
Student of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication - Fatemeh Pirnajafi
Department of Pathobiology School of Public Health Tehran University of Medical Sciences Tehran Iran tums.ac.ir
1 shared publication - Hafez Fakheri
Gut and Liver Research Center, Non-Communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran, mazums.ac.ir
1 shared publication - Iradj Maleki
Gut and Liver Research Center, Non-Communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran, mazums.ac.ir
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 2026 (1) , 8828841
Formulation and Evaluation of Liposome‐Encapsulated Lactiplantibacillus plantarum Postbiotics on Gluten‐Induced Celiac Disease in Caco‐2 Cells via Reduction of Zonulin Secretion
Celiac disease (CD) is a severe autoimmune disorder induced by gluten exposure and a complex interplay of environmental contributors and genetics. While a gluten‐free diet (GFD) is the primary approach for managing CD, it is relatively costly, inconvenient, and challenging to follow. Recently, emerging studies have focused on pro‐, pre‐, and postbiotics, which have been demonstrated to break down gluten and provide a protective effect against the damage exerted by gluten. Thus, this study aimed to utilize postbiotic fractions obtained from the probiotic bacterium Lactiplantibacillus plantarum in the management of CD. The efficacy of the resulting postbiotic in both free and liposomal forms has been studied on the Caco‐2 cell line as a model of CD. The particle size and Z potential of liposome‐encapsulated postbiotic were assessed at about 289 ± 9.6 nm and −70.1 ± 3.8 mV, respectively. An encapsulation efficiency (EE, %) of 81.83 ± 3.2% and a sustained release profile were noted for the liposome‐encapsulated postbiotic. The MTT assay was employed to evaluate the cytotoxic effects of free and liposomal postbiotic on Caco‐2 cells. The free and liposomal postbiotic demonstrated less toxicity than gliadin toward the investigated cell line. Importantly, cotreatment of free and liposomal postbiotics with gliadin remarkably reduced the toxic effects of gliadin. The findings of this research revealed that the evaluated postbiotic from L. plantarum , particularly in its liposomal form, can significantly reduce zonulin secretion and have a protective effect against gluten‐induced damage.
- 1 January 2026
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 2026 (1) , 8828841
Open AccessFormulation and Evaluation of Liposome‐Encapsulated Lactiplantibacillus plantarum Postbiotics on Gluten‐Induced Celiac Disease in Caco‐2 Cells via Reduction of Zonulin Secretion
Celiac disease (CD) is a severe autoimmune disorder induced by gluten exposure and a complex interplay of environmental contributors and genetics. While a gluten‐free diet (GFD) is the primary approach for managing CD, it is relatively costly, inconvenient, and challenging to follow. Recently, emerging studies have focused on pro‐, pre‐, and postbiotics, which have been demonstrated to break down gluten and provide a protective effect against the damage exerted by gluten. Thus, this study aimed to utilize postbiotic fractions obtained from the probiotic bacterium Lactiplantibacillus plantarum in the management of CD. The efficacy of the resulting postbiotic in both free and liposomal forms has been studied on the Caco‐2 cell line as a model of CD. The particle size and Z potential of liposome‐encapsulated postbiotic were assessed at about 289 ± 9.6 nm and −70.1 ± 3.8 mV, respectively. An encapsulation efficiency (EE, %) of 81.83 ± 3.2% and a sustained release profile were noted for the liposome‐encapsulated postbiotic. The MTT assay was employed to evaluate the cytotoxic effects of free and liposomal postbiotic on Caco‐2 cells. The free and liposomal postbiotic demonstrated less toxicity than gliadin toward the investigated cell line. Importantly, cotreatment of free and liposomal postbiotics with gliadin remarkably reduced the toxic effects of gliadin. The findings of this research revealed that the evaluated postbiotic from L. plantarum , particularly in its liposomal form, can significantly reduce zonulin secretion and have a protective effect against gluten‐induced damage.
- Open Access
- 30 October 2023
- Published by Maad Rayan Publishing Company in Middle East Journal of Digestive Diseases
- Vol. 15 (4) , 257-262
Epidemiological, Endoscopic, Clinical, and Pathological Features of Patients with Celiac Diseases in Southern Littoral of Caspian Sea
Background: Celiac disease is an autoimmune disorder resulting from gluten consumption in genetically predisposed individuals. The present study investigated the epidemiological, endoscopic, and clinicopathological features of patients with celiac disease in the southern littoral of the Caspian Sea. Methods: 140 patients with celiac disease were interviewed and examined regarding demographic characteristics, clinical symptoms, and serologic, endoscopic, and pathological findings. Results: 44 (31.4%) of the patients were male and 68.6% were female. The mean age of the patients at diagnosis was 27.13±13.4 years (ranging from 2 to 60 years). The most common gastrointestinal (GI) symptoms were bloating (47.8%), abdominal pain (47.1%) and diarrhea (30.7%), respectively. Also, 17 (12.1%) patients did not complain of any GI symptoms.18 (12.8%) patients had aphthous stomatitis, 10.7% had dermatitis herpetiformis, 3.6% suffered from itching without a rash, two (1.4%) mentioned psoriasis and one (0.7%) had lichen planus. 19 (19.7%) of the female patients complained of menstrual bleeding disorders, 4% mentioned infertility, and 2% experienced primary amenorrhea. The most common comorbid condition was hypothyroidism in 16 (11.4%) patients. The most common endoscopic finding was duodenal scalloping (37.25%). In addition, 7.8% of the patients had a normal endoscopic appearance. 43 (30.7%) patients were classified as Marsh IIIC, 25.7% Marsh IIIB, 17.8% Marsh IIIA, 12.8% Marsh II and 12.8% were classified as Marsh I. Conclusion: Since celiac disease can present with non-GI manifestations and the majority of our patients had Marsh III classification, it seems that celiac disease must be considered as a routine screening test in GI clinics, and also, it should be kept in mind as a differential diagnosis in other specialty fields.
- 30 October 2023
- Published by Maad Rayan Publishing Company in Middle East Journal of Digestive Diseases
- Vol. 15 (4) , 257-262
Open AccessEpidemiological, Endoscopic, Clinical, and Pathological Features of Patients with Celiac Diseases in Southern Littoral of Caspian Sea
Background: Celiac disease is an autoimmune disorder resulting from gluten consumption in genetically predisposed individuals. The present study investigated the epidemiological, endoscopic, and clinicopathological features of patients with celiac disease in the southern littoral of the Caspian Sea. Methods: 140 patients with celiac disease were interviewed and examined regarding demographic characteristics, clinical symptoms, and serologic, endoscopic, and pathological findings. Results: 44 (31.4%) of the patients were male and 68.6% were female. The mean age of the patients at diagnosis was 27.13±13.4 years (ranging from 2 to 60 years). The most common gastrointestinal (GI) symptoms were bloating (47.8%), abdominal pain (47.1%) and diarrhea (30.7%), respectively. Also, 17 (12.1%) patients did not complain of any GI symptoms.18 (12.8%) patients had aphthous stomatitis, 10.7% had dermatitis herpetiformis, 3.6% suffered from itching without a rash, two (1.4%) mentioned psoriasis and one (0.7%) had lichen planus. 19 (19.7%) of the female patients complained of menstrual bleeding disorders, 4% mentioned infertility, and 2% experienced primary amenorrhea. The most common comorbid condition was hypothyroidism in 16 (11.4%) patients. The most common endoscopic finding was duodenal scalloping (37.25%). In addition, 7.8% of the patients had a normal endoscopic appearance. 43 (30.7%) patients were classified as Marsh IIIC, 25.7% Marsh IIIB, 17.8% Marsh IIIA, 12.8% Marsh II and 12.8% were classified as Marsh I. Conclusion: Since celiac disease can present with non-GI manifestations and the majority of our patients had Marsh III classification, it seems that celiac disease must be considered as a routine screening test in GI clinics, and also, it should be kept in mind as a differential diagnosis in other specialty fields.
- 9 April 2021
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (1S) , e1078-e1079
Gastrointestinal symptoms and upper endoscopy findings in systemic lupus erythematous
An abstract is unavailable. This article is available as a PDF only.
- 9 April 2021
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (1S) , e1078-e1079
Gastrointestinal symptoms and upper endoscopy findings in systemic lupus erythematous
An abstract is unavailable. This article is available as a PDF only.